stockportfolio.pro
Catalyst Pharmaceuticals, Inc. P/E Ratio 2002–2025
Catalyst Pharmaceuticals, Inc. (CPRX) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +0.5%/yr over 23 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 13.89 | -12.8% |
| FY 2024 | 15.93 | -40.3% |
| FY 2023 | 26.68 | +7.6% |
| FY 2022 | 24.80 | +35.5% |
| FY 2021 | 18.30 | +289.0% |
| FY 2020 | 4.70 | -62.4% |
| FY 2019 | 12.50 | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
| FY 2008 | — | — |
| FY 2007 | — | — |
| FY 2006 | — | — |
| FY 2005 | — | — |
| FY 2004 | — | — |
| FY 2003 | — | — |
| FY 2002 | — | — |
Source: Catalyst Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Catalyst Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCatalyst Pharmaceuticals, Inc. — frequently asked questions
What is Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio?
Catalyst Pharmaceuticals, Inc. (CPRX) reported price-to-earnings ratio of 13.89 for fiscal year 2025, per its SEC filings.
How has Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2002 and 2025, CPRX's price-to-earnings ratio grew at roughly 0.5% per year (compound annual rate), from 12.50 to 13.89.
Where does this data come from?
Figures are computed from Catalyst Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.